Tvardi Therapeutics Inc (TVRD)

Currency in USD
1.0100
-0.0900(-8.18%)
Closed·
1.0000-0.0100(-0.99%)
·
Advertisement
TVRD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.01001.0800
52 wk Range
0.77295.6900
Key Statistics
Prev. Close
1.1
Open
1.0706
Day's Range
1.01-1.08
52 wk Range
0.7729-5.69
Volume
71.17K
Average Volume (3m)
237.21K
1-Year Change
-75.4854%
Book Value / Share
1.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TVRD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.8750
Upside
+778.71%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Tvardi Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

7 Buy
1 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.8750
(+778.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy10.00+890.10%-Maintain16/11/2026
Chardan
Buy8.00+692.08%-New Coverage20/10/2026
Lucid Capital Markets
Buy14.00+1,286.14%-New Coverage08/09/2026
H.C. Wainwright
Buy9.00+791.09%-Maintain17/08/2026
Piper Sandler
Buy13.00+1,187.13%3.00Upgrade08/07/2026

Tvardi Therapeutics Inc SWOT Analysis


Strategic Pivot
Cara Therapeutics refocuses on oral difelikefalin for notalgia paresthetica, streamlining operations amidst challenges with Korsuva commercialization
Financial Outlook
Despite Q1 2024 losses, Cara projects cash reserves to fund operations into 2026, aligning with crucial KOURAGE Phase III study results timeline
KOURAGE Trial Impact
Upcoming Part A results of KOURAGE Phase 3 trial viewed as critical inflection point, with potential to significantly boost investor confidence
Market Potential
Analysts project peak sales of $630M by 2035 for oral DFK in notalgia paresthetica, with price targets ranging from $1 to $10 per share
Read full SWOT analysis

Tvardi Therapeutics Inc Earnings Call Summary for Q4/2023

  • Cara Therapeutics focuses on notalgia paresthetica treatment, with Phase 2/3 COURAGE I study results expected in Q3 2023
  • Cash runway extended into 2026 despite anticipated restrictions on KORSUVA injection due to reimbursement changes
  • Company considering partnership opportunities for future business development amid reduced demand for KORSUVA in the US
  • Cash and equivalents decreased to $100.8 million from $156.7 million in 2022; G&A expenses flat at $6.6 million for Q4 2023
  • Management confident in clinical and commercial potential of NP program, prioritizing resources on neuropathic pruritus
Last Updated: 05/03/2024, 10:16
Read Full Transcript

Earnings

Latest Release
13/11/2026
EPS / Forecast
-0.48 / -0.55
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare TVRD to Peers and Sector

Metrics to compare
TVRD
Peers
Sector
Relationship
P/E Ratio
−0.5x−0.1x−0.2x
PEG Ratio
−0.030.000.00
Price/Book
0.9x0.9x2.6x
Price / LTM Sales
-2.1x2.7x
Upside (Analyst Target)
-128.9%68.5%
Fair Value Upside
Unlock28.8%11.5%Unlock

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
528.52K3.96%581.38K
Other Institutional Investors
4.58M34.34%5.04M
Public Companies & Retail Investors
8.23M61.70%9.05M
Total
13.34M100.00%14.67M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Sporos Bioventures6.28%837,636921
Solas BioVentures5.71%761,287837

People Also Watch

0.437
XXII
-11.40%
0.2218
REKR
+2.21%
0.2959
EYPT
-3.80%
0.0352
KPTIQ
+23.08%

FAQ

What Is the Tvardi Therapeutics (NASDAQ: TVRD) Share Price Today?

The Tvardi Therapeutics stock price today is 1.0100 USD.

What Stock Exchange Does Tvardi Therapeutics (TVRD) Trade On?

Tvardi Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Tvardi Therapeutics?

The stock symbol (also called a 'ticker') for Tvardi Therapeutics is "TVRD."

What Is the Current Tvardi Therapeutics Market Capitalisation?

As of today, Tvardi Therapeutics (NASDAQ: TVRD) market cap is 14.6700M USD.

What Is Tvardi Therapeutics's (TVRD) Earnings Per Share (TTM)?

The Tvardi Therapeutics EPS is currently -2.61 (Trailing Twelve Months).

When Is the Next Tvardi Therapeutics Earnings Date?

Tvardi Therapeutics's next earnings report will be released on 06/04/2027.

Is TVRD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Tvardi Therapeutics moving averages and other technical indicators, the daily buy/sell signal for TVRD stock is Strong Sell.

How Many Times Has Tvardi Therapeutics Stock Split?

Tvardi Therapeutics has split 2 times. (See the TVRD stock split history page for full effective split date and price information.)

How Many Employees Does Tvardi Therapeutics Have?

Tvardi Therapeutics has 12 employees, based on their latest Companies House report.

What is the current trading status of Tvardi Therapeutics (NASDAQ: TVRD)?

As of 18/11/2026, Tvardi Therapeutics (TVRD) is trading at a share price of 1.0100 USD, with a previous close of 1.1000 USD. The stock has fluctuated within a day range of 1.0100 USD to 1.0800 USD, while its 52-week range spans from 0.7729 USD to 5.6900 USD.

What Is Tvardi Therapeutics (TVRD) Price Target According to Analysts?

The average 12-month price target for Tvardi Therapeutics is 8.8750 USD, with a high estimate of 14 USD and a low estimate of 3 USD. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +778.71% Upside potential.

What Is the TVRD Premarket Price?

TVRD's last pre-market stock price is 1.0800 USD. The pre-market share volume is 710.0000, and the stock has decreased by -0.0200, or -1.8200%.

What Is the TVRD After Hours Price?

TVRD's last after hours stock price is 1.0000 USD, the stock has decreased by -0.0100, or -0.9900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.